Hormone therapy and cardiovascular disease: Benefits and harms

Menopause transition marks an important phase in life when cardiovascular risk in women gradually takes an adverse turn. Although menopausal hormone therapy has gained a negative appreciation over the last decades, its value in the treatment of disabling vasomotor symptoms is still undisputed. Cardiovascular risk assessment has become a matter of precision medicine, which is helpful for safe menopausal hormone therapy prescription. With a multidisciplinary approach the current available hormone regimens can be even given to women at intermediate cardiovascular risk, when risk factors such as hypertension and dyslipidemia are adequately monitored and treated. (c) 2021 The Author. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons. org/licenses/by/4.0/).

Automated summary

The menopause transition marks an important phase in a woman's life where cardiovascular risk gradually turns adverse. Despite negative views on menopausal hormone therapy in recent decades, its value in treating disabling vasomotor symptoms remains undisputed. Cardiovascular risk assessment has become a matter of precision medicine, which is helpful for safe prescription of menopausal hormone therapy.